Press release
Atopic Dermatitis Market Overview 2025 and Growth US$ 31.68 Bn by 2033 | Japan Insights
Atopic Dermatitis Market
Latest Japan‐Related News
Japan's top eczema app "Atopiyo" expands to the US - the app, developed in Japan, is now internationally available
Dupixent (dupilumab) receives approval in Japan for treating atopic dermatitis and other conditions
Maruho to co-develop topical biologic B244 in Japan through a licensing deal with AOBiome
Tapinarof cream (Vtama) approved in Japan for atopic dermatitis in patients 12+
Unlock exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://datamintelligence.com/download-sample/atopic-dermatitis-market?kb
Recent Industry Trends (2025)
Gilead and LEO Pharma Collaboration (Jan 2025): A strategic partnership was formed to advance the STAT6-targeted oral small molecule program aimed at treating inflammatory skin disorders, including atopic dermatitis.
Eli Lilly Acquires Dice Therapeutics (Mar 2025): This acquisition strengthens Lilly's dermatology pipeline by incorporating oral IL-17 inhibitors, expanding therapeutic options for atopic dermatitis (AD).
AI-Powered Dermatology Tools: Artificial intelligence-based skin scanners have been integrated into dermatology applications, enabling real-time skin health monitoring. These tools are increasingly being used in both U.S. and Japanese clinics.
Decentralized Clinical Trials: The adoption of virtual and remote clinical trials continues to grow in 2025. This approach has improved patient recruitment and retention in AD trials by offering virtual consultations and remote monitoring.
Atopic Dermatitis Market Overview
The Atopic Dermatitis encompasses the global industry focused on the diagnosis, treatment, and management of atopic dermatitis (also known as eczema)-a chronic inflammatory skin condition characterized by dry, itchy, red, and inflamed skin. This market includes topical treatments, systemic drugs (like biologics and JAK inhibitors), and emerging digital health solutions
Research Methodology:
The global Atopic Dermatitis Market research report is based on a combination of primary and secondary data sources. The study carefully analyzes various factors influencing the industry, including government regulations, market dynamics, competitive landscape, historical trends, current conditions, and technological progress. It also evaluates future developments, related industry trends, market volatility, growth prospects, potential obstacles, and emerging challenges.
Segment Covered in the Atopic Dermatitis Market:
By Treatment Type: Corticosteroids, Hydrocortisone, Mometasone, Betamethasone, Prednisone, Others , Immunosuppressants , Calcineurin Inhibitors , Cyclosporine, Tacrolimus, Pimecrolimus, Others , JAK Inhibitors , Abrocitinib, Upadacitinib, Others , PDE-4 Inhibitors , Others , Biologics , Dupilumab , Tralokinumab, Others, Antihistamines, Others , , By Patient Type, Children, Adults
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/atopic-dermatitis-market?kb
List of the Key Players in the Atopic Dermatitis Market:
Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., AbbVie Inc., Eli Lilly and Company, Galderma Inc., LEO Pharma Inc., Incyte Corporation, Arcutis Biotherapeutics, Inc., Otsuka Pharmaceutical Co., Ltd, and others.
Atopic Dermatitis Market Emerging Players
The emerging players in the atopic dermatitis market include Almirall, S.A, Aclaris Therapeutics Inc, Kiniksa Pharmaceuticals, Cara Therapeutics, VYNE Therapeutic and among others.
Key Developments in the Atopic Dermatitis Market
April 2025 - Galderma's DTC Campaign: Galderma launched "Scratch Resistance," its first multichannel direct-to-consumer campaign for NEMLUVIO (nemolizumab-ilto). The initiative emphasizes the broader emotional and lifestyle challenges of living with atopic dermatitis, beyond the physical itch.
March 2025 - Amgen & Kyowa Kirin: New insights emerged from the ROCKET Phase 3 trial of rocatinlimab, a therapy that targets the OX40 receptor to rebalance T-cell activity in moderate-to-severe AD patients.
January 2025 - FDA Approves Nemluvio: The U.S. FDA approved Nemluvio (nemolizumab-ilto), a novel IL-31 inhibitor by Galderma, for adolescents and adults with moderate-to-severe atopic dermatitis who are unresponsive to topical therapies.
September 2024 - EBGLYSS Approval: Eli Lilly received FDA approval for EBGLYSS (lebrikizumab-lbkz), an IL-13 inhibitor designed to treat patients aged 12 and older with moderate-to-severe AD not controlled by topical prescriptions.
April 2024 - Dermavant's VTAMA sNDA: Dermavant announced FDA acceptance of its supplemental NDA for VTAMA (tapinarof) cream, 1%, targeting AD in patients aged 2 and older. A final decision is expected by Q4 2024.
July 2024 - ZORYVE Cream Approval: Arcutis Biotherapeutics secured FDA approval for its sNDA for ZORYVE (roflumilast) cream, 0.15%, offering a non-steroidal treatment for mild-to-moderate AD in patients aged 6 and above. The cream delivers fast relief and supports long-term disease management.
Regional Analysis for Atopic Dermatitis Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
The Report Includes:
➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.
➡ Top-down and bottom-up approach for regional analysis
➡ Go-to-market Strategy.
➡ Neutral perspective on the market performance.
➡ Customized regional/country reports as per request and country level analysis.
➡ Potential & niche segments and regions exhibiting promising growth covered.
People Also Ask:
➠ What are the global sales, production, consumption, imports, and exports in the Atopic Dermatitis market?
➠ Who are the top manufacturers, and what are their capacity, production, sales, pricing, and revenue stats?
➠ What key opportunities and challenges do vendors face in the Atopic Dermatitis industry?
➠ Which product types, applications, or end-users are driving market growth, and what is their market share?
➠ What are the major growth drivers and restraints of the Atopic Dermatitis market?
Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atopic Dermatitis Market Overview 2025 and Growth US$ 31.68 Bn by 2033 | Japan Insights here
News-ID: 4076725 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Collagen Market Overview Till 2031: Global Trends, Japan Growth & Future Project …
The Global Collagen Market reached US$ 6.71 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 17.08 billion by 2031 exhibiting a CAGR of 8.3% during the forecast period (2024-2031).
Latest News in Japan:
New Type II collagen supplement "Collexin‐J" launching in Tokyo by Q3 2025:
Japanese nutraceutical company Nippon CellTech developed a next-gen Type II collagen capsule via fermentation to improve bioavailability and support elderly…
Polyethersulfone (PES) Market Overview & Growth $ 658.5 Mn by 2031 | Japan Techn …
Global Polyethersulfone (PES) Market reached US$ 368.4 million in 2022 and is expected to reach US$ 658.5 million by 2031, growing with a CAGR of 7.6% during the forecast period 2024-2031.
Japan News (Latest updates related to PES / sulfone polymers)
Sumitomo Chemical to Build PES Plant in Chiba
Sumitomo Chemical has announced a new Polyethersulfone (PES) production facility at its Chiba Works in Ichihara City, with a capacity of 3,000 t/year, doubling…
Fructo-Oligosaccharides Market by Application: Food, Beverage, Pharma | Japan In …
Global Fructo-Oligosaccharides Market reached US$ 3.21 billion in 2022 and is expected to reach US$ 5.99 billion by 2031, growing with a CAGR of 8.1% during the forecast period 2024-2031.
Latest Japan‐FOS
Meiji's chocolate innovation:
In June 2024, Meiji replaced sugar in its Milk Chocolate 50 and 100 with FOS, aiming to improve gut flora without affecting blood glucose. These chocolates were certified under Japan's Foods with Function Claims by the Consumer Affairs…
Rhizobium Market Size Analysis: Trends, Growth, Projections US$ 1.93Bn by 2031 i …
Global Rhizobium Market reached US$ 1.24 billion in 2022 and is expected to reach US$ 1.93 billion by 2031, growing with a CAGR of 5.71% during the forecast period 2024-2031.
Latest News in Japan:
Oscillating Gene Rhythms in Legume-Rhizobia Symbiosis
Researchers in Japan have discovered that root gene expression in legumes oscillates on a six‐hour rhythm during Rhizobium infection. This rhythmic expression governs where root nodules form and is regulated by the plant…
More Releases for Atopic
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an…
Atopic Dermatitis (Atopic Eczema) Treatment Market Business Growth And Industry …
Precision Business Insights published a research report on “Atopic Dermatitis (Atopic Eczema) Treatment Market by Drug type (Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Phosphodiesterase type 4 (PDE-4) Inhibitors, Antibiotics, Antihistamines, Emollients), Route of administration (Oral, Topical, Parenteral), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography - Global/Region/Country Forecast to 2027”.
In people who suffer from atopic dermatitis, allergies play a big influence. When the patient is exposed to…
Current research: Demand for Atopic Dermatitis Treatment Market rapidly growing …
Report Ocean released a report deciphering the Atopic Dermatitis Treatment Market report that provides in-depth analysis and crucial insights into key factors that are crucial to the success of the market.
The report is a systematic study of the market that provides key statistics on trends, analyst views, competitive landscapes, and key regions markets report is a comprehensive study. In this research report, key business trends and upcoming Atopic Dermatitis Treatment…
Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2018 - ResearchByMarkets …
"Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2018", provides an overview of the Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline landscape.
Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from…
Atopic Dermatitis - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Atopic Dermatitis - Pipeline Review, H2 2017 to its growing collection of premium market research reports.
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Pipeline Review, H2 2017, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.
Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored…
Global Atopic Dermatitis (Atopic Eczema) Treatment Market: Market Estimation, Dy …
Atopic dermatitis is also known as atopic eczema. Atopic dermatitis is a type of inflammatory disease which is of unknown origin usually starts in early infancy, but also affects a major number of adults. Atopic dermatitis results in itchy, red, swollen and cracked skin. Many people with atopic dermatitis may develop hay fever and asthma. The causes are unknown but it is found to involve inherited, immune system dysfunction, environmental…
